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Abstract 
 
Sutherlandia frutescens is a traditional herbal remedy commonly used in South Africa. It 
is used to treat conditions like colds, influenza, fever, diabetes mellitus, liver conditions, 
rheumatism, urinary tract infection (UTI), stress and anxiety, treatment and prevention of 
cancer, treatment of wasting in cancer and patients suffering from acquired immune 
deficiency syndrome (AIDS). Sutherlandia frutescens can also be used topically to treat 
burns, wounds and inflammatory skin conditions.  
Due to its versatility, it is a popular herb of choice for scientific scrutiny. Sutherlandia 
frutescens contains three main constituents, L-canavanine, pinitol and γ-aminobutyric 
acid (GABA). Found in the leaf and seeds, L-canavanine is responsible for the antiviral, 
anti-cancer and anti-inflammatory properties ascribed to Sutherlandia frutescens. Pinitol 
has been recognized for its anti-diabetic and immune modulating effects.  GABA is a non 
essential amino acid and neurotransmitter with anti-anxiety effects. It has therefore been 
indicated for hypertension. There are many studies validating the medicinal value of 
Sutherlandia frutescens on a range of illness conditions, such as viral disease, cancer, 
inflammation and diabetes mellitus.  Focus was placed on the biological activity of 
Sutherlandia frutescens on the immune system by using whole blood cells.  
The aim of this study was to investigate the effects of Sutherlandia frutescens on the 
inflammatory response and T cell differentiation in vitro using cytokines as biomarkers. 
Whole blood cells containing various concentrations of Sutherlandia frutescens were 
stimulated in vitro with either Lipopolysaccharide (LPS) or Phytohaemagglutinin (PHA). 
Results show that Sutherlandia frutescens is not toxic at any of the concentrations tested. 
The addition of Sutherlandia frutescens at high concentrations to the stimulated whole 
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blood cell cultures reflects a significant down regulation of Interleukin(IL) 6 and IL-10 
compared to the control (P<0.05) hence suppressed the inflammatory and humoral 
immune response. Results obtained for Inteferon-gamma (IFNγ) shows that Sutherlandia 
frutescens is donor specific as it reflects both up and down regulation in the release of 
IFNγ at the concentrations tested. The in vitro data generated by this study supports the 
use of Sutherlandia frutescens in the management of inflammatory conditions and 
allergies such as asthma. However the effects of Sutherlandia frutescens on cell mediated 
immunity was found to be donor specific. Further investigation of Sutherlandia 
frutescens on cellular immunity is advised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
 
Declaration 
 
I, Najwa Kisten, declare that the thesis entitled “The immune-modulating activity of 
Sutherlandia frutescens” is my work and has not been submitted before for any degree or 
examination in any other university, and that all the sources of my information have been 
indicated and acknowledged by complete references. 
 
 
 
 
 
 
 
 
Najwa Kisten       May 2010 
 
 
Signed:……………………………………. 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
 
Acknowledgments 
 
 
In the name of God, the Most Beneficent, the Most Merciful 
 
 
I make shukr to my Creator for granting me the inner strength and ability to fulfill my 
goals. I feel privileged to be chosen to make a contribution to the science world. 
 
I would like to say jazakallah to my father Tougeed, Mother Latiefa, sister Maryam and 
brother M. Zeyn for all their support and understanding throughout my academic life. It is 
their love and constant encouragement that motivates me to do my best. 
 
To professor Pool, my supervisor, a big THANK YOU for believing in and taking me 
under your wing. Your knowledge and love for what you do is inspiring. I am extremely 
grateful to you for providing me with the opportunity and honour to study under your 
guidance. 
 
To my colleague and friend, Yusra Kriel, shukran for standing by me, through thick and 
thin. I couldn’t have asked for a better friend and lab partner. You were the catalyst in my 
post graduate experience.  
 
To all my healthy male donors, thank you. “Your blood” made a significant contribution 
to this study. 
 
To the staff at both Tibb medical centers, Langa and at the Saartjie Baartman, thank you 
for unselfishly availing yourself to the donors and your continuous support. 
 
To my lab colleagues, Razia, Cheryll, Hitesh, Yeukai, Farzana and Mozaffar. Thank you 
for always lending a helping hand in times when I needed it the most.  
 
To my work colleagues, Drr Campbell, Brown, Cassiem, Ma, Leisegang and Perch, Mss 
Petersen and Abrahams, thank you for your understanding. 
 
 
 
I am eternally grateful to you all. Thank you for your support and encouragement. 
 
 
 
 
 
 
 
 
 
 
 
 ix
Table of content        Page no. 
 
Title page          i 
Keywords          ii 
Abbreviations          iii 
Latin abbreviations         iv 
Abstract          v 
Declaration          vii 
Acknowledgements         viii 
 
 
Chapter 1: The biological activity of Sutherlandia frutescens 
 
 
1.1 Introduction        1 
1.2 Medicinal uses of Sutherlandia frutescens    3 
1.3 Dosage         5 
1.4 Constituents of Sutherlandia frutescens     5 
1.4.1 Free amino acids      5 
1.4.2 L-canavanine and GABA     7 
1.4.2.1 L-canavanine      7 
1.4.2.2 GABA       7 
1.4.3 Pinitol        8 
1.4.4 Flavonoids       9 
1.4.5 Triterpenoid saponins      9 
1.4.6 Other compounds      9 
1.5 Studies on Sutherlandia frutescens     9 
1.5.1 Epilepsy and convulsions     10 
1.5.2 Stress        10 
1.5.3 Diabetes mellitus      10 
1.5.4 Cancer        11 
1.5.5 HIV        11 
1.5.6 Inflammation       12 
1.6 Research problem        13 
1.7 Concluding remarks       14 
1.8 References        15 
 
 
Chapter 2: The immune system 
 
 
2.1 Introduction        21  
2.2 Innate immunity        22 
2.2.1 Anatomical barriers      22 
2.2.2 Secretory molecules      23 
2.2.3 Cellular components      23 
 
 
 
 
 x
2.2.3.1 Phagocytosis      24 
2.2.3.2 Inflammation      26 
2.2.3.3 Complement      27 
2.2.3.3.1 The classical pathway   29 
2.2.3.3.2 The lectin pathway    29 
2.2.3.3.3 The alternative pathway   30 
2.2.3.3.4 The membrane attack (lytic) pathway 30 
2.3 Adaptive immunity       31 
2.3.1 B cells        32 
2.3.2 T cells        33 
2.4 Immune homeostasis       34 
2.5 Concluding remarks       35 
2.6 References        36 
 
 
Chapter 3: Validation of whole blood cell assays to monitor immune function 
 
 
3.1 Introduction        41 
 3.1.1 In vitro and in vivo methods     41 
 3.1.2 Sutherlandia frutescens and the immune system  42 
3.2 Methods         44 
 3.2.1 Blood collection       44 
3.2.2 Whole blood cells stimulated with LPS   44 
3.2.3 Whole blood cells stimulated with PHA   44 
3.2.4 Cytotoxicity       45 
3.2.5 Cytokine analysis      45 
 3.3 Results and discussion       46 
  3.3.1 Cytotoxicity       46 
  3.3.2 Inflammatory activity      47 
  3.3.3 Humoral immunity      48 
  3.3.4 Cellular immunity      49 
 3.4 Concluding remarks       50 
3.5 References        51 
 
 
Chapter 4: The screening of Sutherlandia frutescens for immune modulating activity 
using in vitro whole blood culture assays 
 
 
3.1 Introduction        54 
3.2 Methods         55 
3.2.1 Preparation of Sutherlandia frutescens    55 
3.2.2 Blood collection       56 
3.2.3 Whole blood cells stimulated with LPS   56  
3.2.4 Whole blood cells stimulated with PHA   56 
 
 
 
 
 xi
3.2.5 Cell culture       57 
3.2.6 Cytotoxicity       57 
3.2.7 Cytokine analysis      58 
3.2.8 Statistical analysis      59  
3.3 Results         59 
3.3.1 Cytotoxicity       59  
3.3.2 The inflammatory activity of Sutherlandia frutescens  60 
3.3.3 The effects of Sutherlandia frutescens on humoral activity 61 
3.3.4 The effects of Sutherlandia frutescens on cellular immunity 62 
3.4 Discussion         64 
3.5 Concluding remarks       68 
3.6 References        69 
 
 
Chapter 5: Summary, concluding remarks and recommendations 
 
 
4.1 Summary         74 
4.2 Concluding remarks       75 
4.3 Recommendations       76 
 
 
List of figures 
 
Figure 1.1: Photograph showing the leaves and flowers of Sutherlandia frutescens 2 
Figure 1.2: Line drawing depicting Sutherlandia frutescens    3 
Figure 2.1: Graphical representation of the cells of the immune system  21 
Figure 2.2: The immune system in acute inflammation    26 
Figure 2.3: The activation of the classical, lectin, and alternative pathways  28 
Figure 2.4: Expansion of antigen specific naïve TH0 cells    33 
Figure 3.1: Standard curve for cytotoxicity      46 
Figure 3.2: Standard curve for IL-6       47 
Figure 3.3: Standard curve for IL-10       48 
Figure 3.4: Standard curve for INF γ       49 
 
 
List of tables 
 
Table 1: Alphabetical list of human systems affected by the anecdotal and/or traditional 
uses of Sutherlandia frutescens      4 
 
 
 
 
 
 
 
 
 
 
 xii
List of bar graphs 
 
Figure 4.1: The effects of Sutherlandia frutescens on the release of IL-6  60 
Figure 4.2: The effects of Sutherlandia frutescens on the release of IL-10  61 
Figure 4.3: The effects of Sutherlandia frutescens on the release of INF γ  62 
Figure 4.4: The effects of Sutherlandia frutescens on the release of INF γ  63 
 
 
 
 
 
 
 
  
 
1 
Chapter I: The biological activity of Sutherlandia frutescens 
 
1.1 Introduction 
Sutherlandia frutescens is commonly used as a traditional herbal remedy in South Africa. It is 
a well known multipurpose medicinal plant (Fernandes, et al., 2004; Ojewole, 2008).  Widely 
known as cancer bush, Sutherlandia frutescens has been used in traditional medical systems 
of different cultural groups such as Zulu, Xhosa, Sotho, Khoi-San and Cape Dutch for a wide 
variety of illness conditions (van Wyk and Albrecht, 2008). 
This versatile medicinal herb is indigenous to Africa.  It is found in the southern parts of 
Namibia, the extreme southeastern corner of Botswana, the western, central and eastern parts 
of South Africa and most of Lesotho.  Sutherlandia tomentosa, a second species, has a 
restricted distribution and is localized along the Cape coast (van Wyk and Albrecht, 2008). 
Both species are used in traditional medicine.  
 
Because of the wide distribution range of Sutherlandia frutescens, it is known by several 
vernacular names in different languages.  In English, it is known as cancer bush, 
sutherlandia, balloon pea and turkey flower.  In Afrikaans, it is known as kankerbos, gansies, 
grootgansies, wildekeur(tjie), keurtjie, rooikeurtjie, kalkoen(tjie)bos, kalkoenblom, belbos, 
kalkoenbelletjie, klapperbos, bitterbos, eentjies and hoenderbelletjie.  In German, it is known 
as blasenstrauch, krebsbusch and sutherlandia.  In Sesotho, it is known as musa-pelo, ‘musa-
pelo-oa-noka and motlepelo.  In Setswana, it is known as phetola.  In Zulu, it is known as 
insiswa, and in Xhosa, it is known as unwele (van Wyk and Albrecht, 2008). 
Recent taxonomic data suggest that Sutherlandia frutescens is synonymous to Lessertia 
frutescens (Matsabisa, 2006; van Wyk, 2008).  There are countless regional forms, genotypes 
and chemotypes represented by the species of Sutherlandia frutescens (van Wyk, 2008). 
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Sutherlandia frutescens comprises of six taxa all of which are endemic to southern Africa 
(Moshe, et al., 1998).  Habitat, orientation of the fruit stipe, the shape of the pod and the 
shape and pubescence of the leaflets are the taxonomically significant characters used to 
distinguish the taxa.  Moshe, et al. (1998) used horizontal starch gel electrophoresis to 
examine the genetic diversity of Sutherlandia frutescens var.incana, Sutherlandia 
microphylla, Sutherlandia speciosa, Sutherlandia humilis, Sutherlandia montana and 
Sutherlandia frutescens.  
 
Sutherlandia frutescens, (figure 1.1 and 1.2) is a perennial shrub which grows up to 2m in 
height (van Wyk and Wink, 2004).  It is a flowering shrub of the pea family 
(Fabaceae/Leguminosa) (Sia, 2004).  The stems are prostrate to erect with compound pinnate 
leaves and leaflets that are oblong to linear elliptic.  The leaves are three or more times longer 
than wide, slightly to densely hairy and silvery in appearance.  The flowers are bright red and 
the fruit resembles inflated bladder-like, papery pods (Gericke, et al., 2001; van Wyk and 
Albrecht, 2008).  The seeds are black, flattened and approximately 3mm in diameter (van 
Wyk and Albrecht, 2008). 
 
 
Figure 1.1: Photograph showing the leaves and flowers of Sutherlandia frutescens 
(Matsabisa, 2006) 
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Figure 1.2: Line drawing depicting Sutherlandia frutescens (Matsabisa, 2006) 
 
1.2 Medicinal uses of Sutherlandia frutescens 
Sutherlandia frutescens is commonly used as a medicinal plant in South Africa (Fernandes, et 
al., 2004; Mills, et al., 2005; Ojewole, 2004; van Wyk and Albrecht, 2008).  The aerial parts 
of Sutherlandia frutescens are used in traditional medicine for the management, treatment 
and/or control of various human ailments in various systems (Ojewole, 2008).  The systems 
affected, along with the anecdotal and traditional uses of Sutherlandia frutescens are 
summarized in Table 1. 
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Table 1: Alphabetical list of human systems affected by the anecdotal and/or traditional uses of 
Sutherlandia frutescens 
System affected Anecdotal and/or traditional uses 
Cardio-vascular 
system 
Heart failure, piles, rheumatism, varicose veins (Gericke, et al., 2001, van 
Wyk and Albrecht, 2008). 
Central nervous 
system 
Ailments of the eye, convulsions, depression, irritability and anxiety, 
Mental and emotional stress, shock, trauma (Gericke, et al., 2001; Mills, et 
al., 2005). 
Endocrine  
System 
Adaptogen, diabetes, menopausal symptoms (Gericke, et al., 2001; van 
Wyk and Albrecht 2008; van Wyk and Wink 2004).    
Gastrointestinal 
tract 
Constipation, diarrhoea, dysentery, gastritis, indigestion, oesophagitis, liver 
conditions, peptic ulcers, poor appetite, reflux (van Wyk and Albrecht 
2008; van Wyk and Wink 2004).    
Immune system Cancer tonic, chickenpox, fever, malignant tumors, wasting in AIDS and 
cancer patients (Gericke, et al., 2001; Mills, et al., 2005; van Wyk and 
Albrecht 2008). 
Integumentary 
system 
Inflammatory skin conditions, topical burns, wounds (Gericke, et al., 2001; 
van Wyk and Wink 2004). 
Musculo-skeletal 
system 
Backache, gout, rheumatoid arthritis, osteoarthritis (Mills, et al., 2005). 
Respiratory system Asthma, bronchitis, cold, cough, Influenza, tuberculosis (Gericke, et al., 
2001; Mills, et al., 2005; van Wyk and Albrecht 2008; van Wyk and Wink 
2004).    
Urogenital tract Cystitis, gonorrhoea (van Wyk and Albrecht 2008; van Wyk and Wink 
2004).    
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1.3 Dosage 
The therapeutic dose of Sutherlandia frutescens is 9mg/kg of body weight (Mills, et al., 2005; 
Seier, et al., 2002).  The dried, ground herb is infused in one litre of boiling water and cooled. 
The infusion is then strained and taken in half tea cup doses (90ml) three times daily 
(Matsabisa, 2006; Mills, et al., 2005).  Children 6-12 years: one quarter tea cup (45ml) three 
times daily (Matsabisa, 2006).  A detailed safety study was conducted by the Medical 
Research Council of South Africa with the aim of investigating the possible toxicity of 
Sutherlandia microphylla leaf powder in vervet monkeys.  Results revealed that Sutherlandia 
microphylla was not associated with toxic or other side effects at one, three and nine times 
the recommended dose which is equivalent to 9, 27 and 81mg/kg of body weight respectively 
(Seier, et al., 2002). 
 
1.4 Constituents of Sutherlandia frutescens 
1.4.1 Free amino acids 
The leaves of Sutherlandia frutescens contain high levels of free and protein bound amino 
acids (Moshe, 1998; van Wyk, 2008).  Analysis of the leaves of commercial Sutherlandia 
frutescens grown at different localities showed high levels of the free amino acids asparagine 
(1.6-35.0 mg/g), proline (0.7-7.5mg/g) and arginine (0.5-6.7mg/g) (van Wyk and Albrecht, 
2008). The presence of arginine is of particular importance because of its biological 
activities.   
 
Arginine is considered a non-essential amino acid as the body produces it naturally (Boom, et 
al., 2008).  Free arginine is an important signaling molecule in both animals and plants.  In 
plants, arginine is converted to nitrous oxide (NO) by a group of enzymes called nitric oxide 
synthases.  NO can also be synthesized from nitrite using nitrate reductase (Bethke, et al., 
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2004).  NO is an important signaling molecule that acts on many tissues to regulate a wide 
range of physiological and cellular processes.  The endogenous production of NO plays a 
vital role in influencing physiological processes (Abramson, 2005) such as vasodilation.  NO 
production is suggested to be beneficial in the treatment or management of illness conditions 
that improve with vasodilation (Boom, et al., 2008).  Increasing evidence indicates that NO 
also plays a complex role in modulating the inflammatory response (Abramson, 2005).  
Arginine is also active against viral infections, including Coxsakie virus due to its 
contribution to NO synthesis.  However, increased NO production can lead to NO-induced 
cytotoxicity by oxidative injury, resulting in cellular and organ dysfunctions.  Thus, arginine 
may be beneficial or harmful to the body and the question of its safety could be related to the 
dose administered (Sia, 2004). 
 
Goret, et al. (2008) designed a study in which they tested the hypothesis that a decrease in 
arginine bioavailability could be involved in hypoxia induced pulmonary hypertension.  This 
is said to be associated with an impairment of NO mediated vasorelaxation in the pulmonary 
circulation that is not prevented by exercise. These results confirmed that there is a potential 
beneficial effect of exercise on NO mediated pulmonary artery vasorelaxation, as it is partly 
blunted by the harmful effects of hypoxia on arginine bioavailability (Goret, et al., 2008).  
 
1.4.2 L-canavanine and GABA 
1.4.2.1 L-canavanine 
L-canavanine is a common compound recorded in members of the legume family (van Wyk 
and Albrecht, 2008).  It is one of three principle constituents of Sutherlandia frutescens 
(Mills, et al., 2005).  High levels of L-canavanine in Sutherlandia frutescens leaves were 
discovered by Moshe (1998).  The levels of L-canavanine in the leaves vary from 0.42mg/g 
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to 14.5 mg/g (Moshe, 1998) and about 1.3-3.1 mg/g dry weight in commercial preparations of 
Sutherlandia frutescens (van Wyk, 2008).  
L-canavanine is a compound that may be responsible for the anti-cancer and anti-
inflammatory properties ascribed to Sutherlandia frutescens.  L-canavanine also has an anti-
cancer capacity that has been found to abate pancreatic cancer (Sia, 2004).  Its major 
metabolite, canaline is being developed as a potentially new anti-cancer drug for pancreatic 
cancer (Reid, et al., 2006).  L-canavanine is reported to have anti-viral activities against 
influenza and retroviruses including HIV (Mills, et al., 2005). 
L-canavanine is able to prevent the arginine-derived synthesis of NO (Anfossi, et al., 1999).  
It is a potent arginine antagonist and is also a selective inhibitor of inducible NO synthase.  It 
therefore has a possible application in the treatment of septic shock and chronic 
inflammation. 
 
1.4.2.2 GABA 
GABA is both an amino acid and an inhibitory neurotransmitter that acts outside the central 
nervous system (Sia, 2004; Mills, et al., 2005).  It is a non-protein amino acid that is 
biologically important (Chemistry 108B, 2005) as it is responsible for most of the brain’s fast 
inhibitory transmission (Jocham  and Ullsperger, 2008).  According to van Wyk and Albrecht 
(2008) commercial samples of Sutherlandia frutescens contain 0.23-0.85mg/g of GABA. 
The presence of GABA could partly account for Sutherlandia frutescens’ use in the treatment 
of stress and anxiety (van Wyk and Albrecht, 2008).  Stress related ailments are known to be 
linked to the endocrine system.  It was suggested by Tai, et al. (2004) that GABA could play 
a role in elevating the mood of patients suffering from a chronic illness.  Prevoo, et al. (2008) 
recently showed that Sutherlandia frutescens may reduce the adrenal P450 enzyme, and thus 
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indicate a possible mechanism by which symptoms of stress and glucocorticoid levels are 
reduced.  
 
1.4.3 Pinitol  
Moshe (1998) reported a level of pinitol of up to 14 mg/g per dry leaves.  Pinitol is one of 
three principle constituents of Sutherlandia frutescens.  It is a type of sugar found in many 
legumes and is classified as chiro-inositol (Mills, et al., 2005).  It has been recognized for its 
anti-diabetic and immune modulating effects by interacting with dendritic cell maturation 
(Catelani, et al., 2008).  Pinitol exerts an insulin like effect resulting in a decreased level of 
blood glucose, hence an increased availability of glucose for cell metabolism (van Wyk and 
Albrecht, 2008).  Kim, et al. (2007) evaluated the effect of pinitol therapy in type 2 diabetic 
patients who were poorly controlled with hypoglycemic drugs.  After a 12 week pinitol 
treatment (20 mg/kg daily), fasting glucose and post prandial glucose levels were 
significantly decreased, indicating that pinitol treatment can alter glucose metabolism in type 
2 diabetic patients.   
Pinitol has been described as being active against acute edema in rat models and reducing the 
production of pro-inflammatory cytokines, such as TNF- α and IL - 1β (Ojewole, 2004).  
 
1.4.4 Flavonoids  
In an attempt to provide chemical markers for the aerial parts of Sutherlandia frutescens, a 
phytochemical investigation done by Avula, et al. (2010) lead to the identification of four 
flavonoids, sutherlandin A, sutherlandin B, sutherlandin C and sutherlandin D (Avula, et al., 
2010).  Flavonoids occur both in the free state and as glycosides.  These group of constituents 
are the largest group of naturally occurring phenols (Evans, 2002).  Flavonoids are known for 
its anti-inflammatory and anti-allergic effects, for anti-thrombotic and vaso-protective 
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properties, for inhibition of tumour promotion and as a protective for the gastric mucosa 
(Evans, 2002).  
 
1.4.5 Triterpenoid saponins and other compounds 
A minimum of 56 different triterpene glycosides has been found in Sutherlandia frutescens 
(van Wyk and Albrecht, 2008).  Sutherlandia frutescens leaves also contain high levels of 
unidentified polysaccharides (van Wyk and Albrecht, 2008). 
 
1.5 Studies on Sutherlandia frutescens 
1.5.1 Epilepsy/convulsions 
Aerial parts of Sutherlandia frutescens are used in South African traditional medicine for 
various illnesses including childhood convulsion and epilepsy.  Ojewole (2008) conducted a 
study in which he examined the anti-convulsant property of Sutherlandia frutescens against 
drug induced seizures in mice.  Phenobarbitoin and Diazepam were used as reference anti-
convulsant drugs.  When compared to the reference anti-convulsant drugs, Sutherlandia 
frutescens shoot aqueous extract, delayed the onset of certain drug induced seizures 
significantly.  The findings of this in vivo study confirms that Sutherlandia frutescens shoot 
aqueous extract has anti-convulsant properties, and may therefore be used as a natural 
supplementary remedy in the management, control and/or treatment of convulsions (Ojewole, 
2008). 
 
1.5.2 Stress 
A study to investigate the influence of Sutherlandia frutescens on the biosynthesis of the 
glucocorticosteroid associated with the symptoms of chronic stress was conducted by Prevoo, 
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et al. (2008).  The results showed a possible mechanism by which Sutherlandia frutescens 
reduces glucocorticoid levels and alleviates symptoms associated with stress.  
 
1.5.3 Diabetes mellitus 
Sutherlandia frutescens is widely used for the treatment of type 2 diabetes mellitus.  It has 
gained recognition as a potential hypoglycaemic agent.  Chadwick, et al. (2007) investigated 
the hypoglycaemic effects of Sutherlandia frutescens in diabetic rats.  Wistar rats received a 
diet specifically designed to induce obesity, insulin resistance and lead to a typical 
prediabetic state.  The rats were then divided into 3 groups.  The first group received 
Metformin.  Metformin is a drug administered to hyperglycaemic individuals.  The second 
group of rats received an infusion made with the leaves of Sutherlandia frutescens, and the 
third group of rats served as a control.  After 8 weeks of medicinal compliance, the rats 
receiving Sutherlandia frutescens in their drinking water displayed normal insulin levels. 
There was a marked increase in glucose uptake into muscles and adipose tissue and a 
significant decrease in intestinal glucose uptake.  The results obtained from this experiment 
indicate that Sutherlandia frutescens extract has beneficial effects on type 2 diabetes. 
 
1.5.4 Cancer 
Sutherlandia frutescens is an old South African herbal remedy which is also traditionally 
used in the treatment of internal cancers, hence the herbs’ common name ‘cancer bush’. 
Extract produced from the leaves have anti-proliferative effects on cancer cells (Sia, 2004).  
A study by Tai, et al. (2004) showed that Sutherlandia frutescens has an anti-proliferative 
effect on several human tumor cell lines.  Crude aqueous whole plant extract of Sutherlandia 
frutescens induce cytotoxicity in cervical carcinoma cells (Chinkwo, 2005) and a significant 
decrease of up to 50% of malignant cell numbers of human breast adenocarcinoma were 
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observed after 24 hour exposure to 1.5mg/ml extract (Stander, et al., 2007).  The aqueous 
extract of Sutherlandia frutescens inhibits the growth of the estrogen dependant cancer cell 
lines.  Ethanolic extracts of commercially prepared Sutherlandia frutescens (tablet and 
powder) have been reported to inhibit proliferation of human breast cancer cells (Steenkamp 
and Gouws, 2006). 
 
1.5.5 HIV/AIDS 
It is stated that in Africa, herbal medicine is often used as primary treatment for HIV/AIDS or 
HIV related symptoms such as dermatological conditions, nausea, insomnia and weakness 
(Mills, et al., 2005).  Recent anecdotes suggest that Sutherlandia frutescens improves the 
quality of life of HIV/AIDS patients by counteracting cachexia (van Wyk, 2008). 
Oosthuizen and van De Venter (2005) screened extracts of Sutherlandia frutescens and 
Lobostemon trigonus to detect if the extracts inhibited the immunodeficiency virus (HIV). 
The study showed that Sutherlandia frutescens extract contains compounds that inhibit HIV 
target enzymes (Oosthuizen and van de Venter, 2005).  According to a study by Brown, et al. 
(2008), Hypoxis hemerocallidea and L-canavanine (amino acid found in Sutherlandia 
frutescens) increases the bioavailability of Nevirapine, an anti-retroviral drug.  This study 
indicates that lower doses of Nevirapine can potentially be used if given in conjunction with 
Sutherlandia frutescens due to the Sutherlandia frutescens induced increase in Nevirapine 
bioavailability. 
 
1.5.6 Inflammation 
The pathogenesis of some inflammatory conditions is due to reactive oxygen species derived 
from phagocytes such as hydrogen peroxide and superoxide radicals.  According to 
Fernandes, et al. (2004), the anti-inflammatory properties of Sutherlandia frutescens can be 
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linked to its antioxidant activity.  However, the study by Tai, et al. (2004) showed no 
significant antioxidant activity.  According to Kundu, et al. (2005), the anti-inflammatory 
property of Sutherlandia Frutescens could be attributed to its ability to inhibit COX-2 
expression.  COX-2 is a rate limiting enzyme involved in inflammation.  According to Sia 
(2004) pinitol reduces the production of pro-inflammatory cytokines such as IFN γ hence 
decrease inflammation.  According to Anfossi, et al. (1999), the anti-inflammatory properties 
of Sutherlandia frutescens can be linked to L-canavanine because it has been noted as a 
potent arginine antagonist.  L-canavanine inhibits the enzyme NO synthase.  Inhibition of this 
enzyme results in vasoconstriction. 
 
1.6 Research problem 
Towards the end of the 19th century, health care systems throughout the world were in 
turmoil.  The existing trend within the healthcare system was geared towards providing 
expensive treatment for a selected few sick individuals, as oppose to basic health care for 
many.  This trend of inequality was found in both developed and developing countries.  In 
response to this world wide outcry, an international conference on primary health care was 
held by World Health Organization (WHO) in collaboration with the United Nations 
Children’s Fund (UNICEF).  The conference was attended by 134 nations including 
government (GO) and non-government organizations (NGO).  At this conference, the 
philosophy of primary health care was endorsed and was seen as a means of achieving 
“universally available health care” (Interdisciplinary teaching and learning, 2010).  
According the WHO website, 80% of Africa’s population relies on traditional herbal 
medicine for primary health care.  The WHO explains some of the challenges facing the use 
of traditional herbal medicine with the main challenge being the lack of scientific data to 
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prove its safety and efficacy.  It is generally assumed by the layman that herbal medicine, 
being natural, is safe and free from side effects and contra-indications without realizing that if 
the medication is taken incorrectly or co-administered with other drugs, adverse reactions can 
occur.  It is for this reason that the necessary information and training with regard to herbs 
and herbal products is of vital importance.  Methods of researching a herb is complex due to 
its numerous phytochemicals.  This requires the use of expensive methods and equipment yet 
it is pertinent to the growth and development of the use of traditional herbal medicine in 
primary health care.  Dr Manto Tshabalala-Msimang, the former South African minister of 
health, issued a draft policy pertaining to the incorporation of African Herbal Medicine into 
the healthcare system. This was noted in the July 2008 edition of the Government Gizette. 
In summary, there is a growing need to investigate the efficacy of commonly used traditional 
herbal medicine by evaluating the physiological properties and scientifically proving its uses. 
This is particularly important in Africa as majority of the population rely on traditional herbal 
medicine for primary health care.  
 
1.7 Concluding remarks 
There are many studies validating the medicinal value of Sutherlandia frutescens on a range 
of illness conditions, such as viral disease, cancer, inflammation and diabetes many of which 
require either the stimulation or inhibition of certain immune pathways.  Scientific data 
relating to the mechanism whereby Sutherlandia frutescens acts on the immune system have 
not been comprehensively documented (Mills, et al., 2005).  Due to this, the following study 
was undertaken to investigate the role of Sutherlandia frutescens, variety microphylla, on the 
immune system. 
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Chapter 2: The immune system 
 
2.1 Introduction 
The immune system of vertebrates consists of multiple physical, chemical and cellular 
components, which in combination provides protection to the body from possible invasion by 
pathogens (Helbert, 2006; Nairn and Helbert, 2005; Paul, 2008).  The main function of the 
immune system is self/non-self discrimination.  The ability to differentiate between the self 
and non-self is necessary to protect the organism from invading pathogens.  Pathogens can 
replicate intra-cellularly (viruses, some bacteria and parasites) or extra-celluarly (most 
bacteria, fungi and parasites).  Due to this, different components of the immune system have 
evolved to protect the organism against various pathogens (Meyer, 2009).  The immune 
components are classified as innate or adaptive.  Both components have co-operative 
mechanisms that work synergistically to eradicate foreign substances (Edgar, 2006).  
 
 
Figure 2.1: Graphical representation of the cells of the immune system (Meyer, 2009). 
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Cells of the immune system (Figure 2.1) originates in the bone marrow, and includes myeloid  
progenitor (stem) cells which gives rise to neutrophils, basophils, eosinophils, macrophages 
and dendritic cells whereas the lymphoid progenitor (stem) cells gives rise to B lymphocytes, 
T lymphocytes and NK cells (Meyer, 2009).  
 
2.2 Innate immunity 
The initial immune response is known as the innate immune system (Griffin, et al., 2003).  It 
is not directed towards specific foreign particles but against general pathogens that enters the 
body (Timmis, et al., 2008).  It plays a crucial role in limiting the early replication and spread 
of pathogens (Le Bon and Tough, 2002).  Cells of the innate immune system trigger the early 
responses to infection.  This response is a powerful nonspecific defense that prevents or 
limits infection by most potentially pathogenic microorganisms (Paul, 2008).  Although the 
innate immune system plays a role in all tissues and organs, its function is more dominant in 
areas that are exposed to the external environment such as the skin, digestive, respiratory and 
genitourinary tracts.  Innate immune defenses are based on cells that are permanently located 
in a specified area of the body and on the migration of additional cells to the site of infection 
where it is needed (Paul, 2008).  Components of the innate immune system include 
anatomical barriers, secretory molecules and cellular components (Meyer, 2009). 
 
2.2.1 Anatomical barriers 
Intact skin and mucous membranes serves as barriers to invading pathogens.  The closely 
packed epithelial cells prevent the entry of pathogens into the body (Helbert, 2006). 
Desquamation of skin epithelium also aids in the removal of bacteria and other infectious 
agents that adhered to the epithelial surface.  Cilia present on epithelium to increase surface 
area or aid in peristalsis ensures the lumen of the respiratory tract, as well as the 
 
 
 
 
  
 
22 
gastrointestinal tract is free from microorganisms.  Epithelial cells not only serve as a 
physical barrier but also secrete antimicrobial peptides that act directly on invading pathogens 
as well as upregulates cytokines and chemokines.  These cytokines and chemokines attract 
additional T and B cells to the site of infection (Meyer, 2009).   
 
2.2.2 Secretory molecules 
Other first line defense mechanisms provided by the body are secretions.  The fatty acids in 
sweat are bacteriostatic (Meyer, 2009).  The mucus secreted by the mucus membranes in the 
respiratory tract traps foreign particles while the cilia lining wafts the trapped foreign matter 
out of the body (Helbert, 2006).  Secretions are also used as a flushing tool, e.g. the washing 
effect of tears and saliva.  Other mechanisms of expulsion of foreign matter involve urination, 
defecation and emesis (Magcwebeba, 2008).  The lysozymes and phospholipase in tears, 
saliva and nasal secretions can break down the cell wall of bacteria and destabilize bacterial 
membranes (Meyer, 2009).  The low pH of sweat and hydrochloric acid in gastric secretions 
provide additional anti-microbial protection (Edgar, 2006; Meyer, 2009).  Defensins, a low 
molecular weight protein found in the lung and gastrointestinal tract have anti-microbial 
activity.  Surfactants in the lung act as opsonins (Meyer, 2009). 
 
2.2.3 Cellular components 
The combined effect of all the first line defense mechanisms makes it challenging for 
pathogens to enter and invade the host’s body (Helbert, 2006).  The normal flora of the skin 
and in the gastrointestinal tract can ward off pathogens by competing for nutrients or 
attachment to cell surfaces or by secreting toxic substances (Meyer, 2009).  However, these 
basic defenses are prone to damage, e.g. injury.  When there is a breech in this barrier, 
pathogens can enter and invade the body (Helbert, 2006) activating the second part of the first 
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line of defense.  This line of defense is mediated through phagocytosis along with 
inflammation and cell lysis. 
 
2.2.3.1 Phagocytosis 
Phagocytosis, driven by the production of nitric oxide (NO) (Bourgeon, et al., 2007), is an 
important pyelogenetic practice of innate immunity.  It is a process in which leukocytes and 
other phagocytic cells ingest particular ligands whose size exceeds 1µm.  Apart from 
phagocytosis, phagocytic cells can also recognize and remove cells that underwent 
programmed cell death (apoptosis) (Henson and Hume, 2006).  Apoptotic cells do not induce 
the expression of inflammatory cytokines in phagocytic cells.  On the contrary, it elicits a 
direct anti-inflammatory effect (M’ajai, et al., 2006).  There are four principles that govern 
the cell death recognition model for the immune system.  Firstly, only antigen that sheds from 
apoptotic or necrotic cells can present to naïve T cells.  Secondly, only apoptotic or necrotic 
cells can attract phagocytic cells.  Thirdly, macrophages or dendritic cells (DC) localized in 
non-lymphoid tissue phagocytose dying/dead cells; migrate to lymphoid tissues and present 
antigen to naïve T cells found in that area.  Lastly, tolerance or adaptive responses are not 
dependent on whether the antigens are self or non-self, but on the ways of cell death during 
antigen presentation (Sun, 2008). 
Two essential immune functions are accomplished when pathogens are ingested by 
phagocytic cells.  Firstly, they initiate a microbial death pathway by routing ingested 
pathogens to hydrochloric rich organelles such as lysosomes.  Secondly, DC (phagocytic 
leukocytes) utilizes phagocytosis to direct antigens to both major histocompatibility complex 
I and II compartments (Greenberg and Grinstein, 2002).  
Agents that penetrate the epithelium are met with macrophages and other phagocytic cells 
possessing “microbial sensors” that recognizes key molecular characteristics of pathogens. 
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These “pattern recognition receptors” include many families of molecules, of which the most 
intensively studied are the toll like receptors (TLRs).  TLRs are composed of at least 10 
members which are widely distributed between inflammatory cells and are able to recognize 
a distinct substance associated with microbial agents: TLR4 recognizes LPS; TLR3, double 
stranded RNA and TLR9, unmethylated CpG-containing DNA (Paul, 2008; Trinchieri, 2003). 
TLRs stimulate phagocytic cells to produce pro-inflammatory cytokines such as TNF, IL-1β 
and IL-6 (Hendricks, 2008).  These cytokines stimulates the macrophages and neutrophils, as 
well as initiate inflammation.  
The influx of phagocytic cells to the site of activity allows many bacteria to be recognized, 
ingested and destroyed. Some bacteria have a polysaccharide capsule that allows them to 
resist direct engulfment by phagocytes.  These bacteria become susceptible to phagocytosis 
only when they are coated with antibody that engages the Fcγ receptors on phagocytic cells 
triggering engulfment and destruction of the bacterium.  The process of coating the 
microorganism with molecules that allows its destruction by phagocytes is called 
opsinization.  The internalization and destruction of microorganisms are enhanced by the 
interaction between the molecules coating an opsonized microorganism and specific receptors 
on the phagocyte surface. When the antibody coated pathogen binds to Fcγ receptors, the 
phagocyte surface extends around the surface of the microorganism. Engulfment of the 
microorganism leads to the formation of an acidified cytoplasmic vesicle known as a 
phagosome. The phagosome then fuses with one or more lysosomes to generate a 
phagolysosome. The release of lysosomal enzymes into the phagosome destroys the 
bacterium (Janeway and Travis, 1994). 
Phagocytes can also damage pathogens by an oxidative mechanism with the production of 
reactive oxygen radicals (Paul, 2008).  The most important of these reactive oxygen radicals, 
which are directly toxic to the bacterium, are hydrogen perioxide (H2O2), superoxides anion 
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(O2) and nitric oxide (NO).  The production of these compounds is induced by the binding of 
aggregated antibodies to Fcγ receptors (Janeway and Travis, 1994). 
The elimination of a pathogen from a system involves the activation and recruitment of 
phagocytic cells to a site of infection where phagocytosis is initiated.  This influx of cells to 
the affected area and the release of bactericidal substances results in inflammation 
(Magcwebeba, 2008).  
 
2.2.3.2 Inflammation 
 
Figure 2.2: The immune system in acute inflammation. The interaction of a range of innate 
and adaptive components contributing to acute the inflammatory processes (Edgar, 2006). 
 
Inflammation describes the body’s immediate response to infection or damage (Edgar, 2006; 
Griffin, et al., 2003; Janeway and Travis, 1994).  It was originally defined by four Latin 
words dolor, rubor, calor and tumor translated as pain, redness, heat and swelling 
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respectively (Janeway and Travis, 1994).  It is triggered by a range of stimuli including 
chemical or thermal damage and infection.  Preformed mediators are released in response to a 
breach in the first line of defense.   This results in immediate aggregation of platelets which is 
associated with the release of serotonin.  This promotes vasoconstriction, further platelet 
aggregation and the formation of a platelet plug.  Other preformed mediators released include 
histamine, heparin, lysosomal enzymes and proteases, neutrophil chemotactic factor and 
eosinophil chemotactic factor.  These factors are responsible for vasodilation, i.e. increase in 
blood flow to the site of injury and the recruitment of specific inflammatory cells to the area 
(Edgar, 2006).  This increase in vascular permeability gives rise to the four clinical signs of 
inflammation; i.e. pain, redness, heat and swelling which is crucial to the early inflammatory 
response and is initiated as a result of the activation of complement (Edgar, 2006; Meyer, 
2009). 
 
2.2.3.3 Complement  
The complement system is a highly sophisticated biological reaction system that plays a vital 
role in both innate and adaptive immunity in jawed vertebrates and serves as an important 
interface between these two systems (Fujita, et al., 2004; Holers and Kulik, 2007). 
Complement can be activated by interactions between the antibody and antigen (Nairin and 
Helbert, 2005).  The complement system has a series of serum proteins circulating in the 
bloodstream (Edgar, 2006; Magcwebeba, 2008; Meyer, 2009).  These serum proteins are 
produced by a variety of cells including, hepatocytes, macrophages and gut epithelial cells. 
Some complement proteins bind to immunoglobulins (Ig) or to membrane component cells 
while others are proenzymes that when activated, cleave one or more other complement 
proteins.  When cleaved, some complement proteins yields fragments that activate cells, 
increase vascular permeability or opsonize bacteria.  Complement activation can be divided 
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into four pathways; the classical pathway, the lectin pathway, the alternative pathway and the 
membrane attack (lytic) pathway.  The classical and alternative pathways lead to the 
activation of C5 convertase and result in the production of C5b.  C5b plays an important role 
in the activation of the membrane attack pathway (Meyer, 2009). 
 
 
 
Figure 2.3:  The activation of the classical, lectin, and alternative pathways (Fujita, et al., 
2004).  The three pathways converge at the cleavage of C3 and the formation of a C5 
convertase, which triggers the final lytic pathway of a C5 convertase, binding lectin-
associated serine protease; MBL, mannose-binding lectin (Edgar, 2006). 
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2.2.3.3.1 The classical pathway 
The classical pathway is activated by the formation of soluble antigen-antibody 
combinations.  The components of the classical pathway are activated in the following 
sequence: C1, C4 followed by C2.  Activation involves the cleavage of each molecule which 
forms an enzyme complex that activates the next molecule and releases molecular fragments. 
The formation of the classical pathway C3 convertase (C4b2a) results in cleavage of C3 and 
the initiation of the terminal pathway.  The cleavage products include C4a which is 
chemoattractants for phagocytes and cause degranulation of mast cells.  Activation of the 
classical pathway recruits other inflammatory cells to the area of activation (Edgar, 2006). 
 
2.2.3.3.2 The lectin pathway 
The lectin pathway is very similar to the classical pathway.  The binding of mannose binding 
lectin (MBL) to bacterial surfaces with mannose-containing polysaccharides (mannans) 
initiates the process.  Binding of MBL to a pathogen results in the association of two serine 
proteases, MASP-1(MBL-associated serine proteases) and MASP-2.  MASP-1 and MASP-2 
are comparable to C1r and C1s respectively, and MBL is comparable to C1q.  Construction 
of the MBL/MASP-1/MASP-2 tri-molecular complex results in the activation of the MASPs, 
hence cleavage of C4 into C4a and C4b.  The C4b fragment binds to the pathogen membrane 
and the C4a fragment is released.  Stimulated MASPs also cleave C2 into C2a and C2b.  C2a 
binds to the pathogen membrane in association with C4b and C2b is released.  The resulting 
C4bC2a complex is a C3 convertase, which cleaves C3 into C3a and C3b.  C3b binds to the 
pathogen membrane in association with C4b and C2a and C3a is released.  The resulting 
C4bC2aC3b is a C5 convertase.  The generation of C5 convertase is the end of the lectin 
pathway(Meyer,2009).       
 
 
 
 
 
  
 
29 
2.2.3.3.3 The alternate pathway 
Another kind of C3 convertase can be formed by the stabilization of a different group of 
proteins (includes C3b – a product of the classical pathway).  A degree of C3 conversion can 
occur, in the absence of classical pathway activation, due to spontaneous hydrolysis enhanced 
by proteases, e.g. plasmin, or other inflammatory products.  The low level of C3 conversion 
makes it possible for the alternative pathway to operate without activation of earlier 
components of the classical pathway.  C3b binds pathogen membranes.  The complex C3b 
forms with factor B in the presence of the protease factor D, i.e. C3bBb, dissociates rapidly 
unless stabilizing factors are present.  These factors include microbial polysaccharides such 
as endotoxin, zymosan, sialic acid-deficient erythrocytes, nephritic factor, aggregated forms 
of IgA and some subclasses of IgG.  The inhibitory factor H constantly acts to separate 
C3bBb but the affinity of C3b is significantly reduced in the presence of stabilizing factors. 
This then acts on C3.  C4 and C3 are structurally homologous as are C2 and factor B.  It is 
thus clear that the alternative pathway takes the form of feedback mechanism that operates 
whenever C3b is formed, and is sustained when factors are present to stabilize the assembly 
of its C3 convertase (Reeves and Todd, 2002).   
 
2.2.3.3.4 The membrane attack (lytic) pathway 
C5 convertase from the classical (C4b2a3b), lectin (C4b2a3b) or alternative (C3bBb3b) 
pathway cleaves C5 into C5a and C5b.  C5a remains in the fluid phase and the C5b swiftly 
links with C6 and C7 and is included into the membrane.  C8 then binds, followed by several 
molecules of C9.  The C9 molecules form an aperture in the membrane through which the 
cellular contents escapes and lysis occurs.  The complex consisting of C5bC6C7C8C9 is 
referred to as the MAC.  C5a generated in the lytic pathway has numerous effective 
biological activities.  It is the most potent anaphylotoxin, and it is a chemotactic factor for 
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neutrophils.  It also stimulates the respiratory burst and inflammatory cytokine production by 
macrophages.  C5a activities are regulated by inactivation by carboxypeptidase B (C3-INA). 
Some of the C5bC6C7 complex formed can detach from the membrane and enter the fluid 
phase.  If it attaches to other nearby cells, cell lysis can occur.  Protein S binds to soluble 
C5bC6C7 thus preventing damage to bystanding cells (Meyer, 2009).  
 
The innate and adaptive systems are interconnected (Nairin and Helbert, 2005).  Phagocytosis 
serves a dual role: as an innate immune effector as well as a link between the innate and 
acquired immune response (Greenberg and Grinstein, 2002).  Innate immune activation 
triggers and paves the way for an adaptive immune response by antigen-specific T and B 
lymphocytes.  Adaptive system dominates when the innate system fails to eradicate the 
invading pathogen or if the pathogen finds a way to avoid interaction with the innate system 
(Nairin and Helbert, 2005).   
 
2.3 Adaptive immunity 
Adaptive immunity has evolved to provide a broader base for recognition of self from non-
self in vertebrates (Bonilla and Oettgen 2010; Nairin and Helbert, 2005).  This is 
accomplished by creating a defense system of recognition molecules that interact with foreign 
antigens which consist of T and B cells (Holers and Kulik, 2007).  The ability of vertebrates 
to generate an anticipatory defense system against foreign molecules is increased in the 
germline that encodes proteins that has binding sites and can function as receptors.  The 
products of these gene duplications is the gene families that encode the antigen-recognition 
molecules (antibodies, T cell receptors, MHC proteins) (Nairin and Helbert, 2005) and this is 
a key feature of the adaptive immune system (Helbert, 2006).  Another key feature of 
adaptive immunity is the generation of immunologic memory.   Long lived memory of T and 
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B cells are established after the first encounter with antigen which yields a more rapid and 
robust protective response in subsequent encounters with the same antigen (Bonilla and 
Oettgen, 2010). 
 
2.3.1 B cells 
The differentiation of B cells is initiated by IL-6 (Hendricks, 2008).  B cells are lymphocytes 
that play a major role in humoural immunity (Pawelec and Larbi, 2008).  The principle 
function of B cells is to create antibodies against antigens.  It thus has a crucial role in antigen 
presentation and cytokine secretion (Nashi, et al., 2010).  Humoral immunity also contributes 
to natural resistance and host defense against certain fungi e.g. Candida albicans (Casadevall, 
et al., 2002).  
B cells are presented as antigen presenting cells (APCs) and express peptides and MHC II on 
their surface (Dorner, et al., 2009).  These peptides arise as a result of processed antigen that 
was engulfed after binding to the B-cell surface immunoglobulin receptor.  T cells can 
activate B cells for differentiation into memory or plasma cells.  B cells and DC express 
many of the same costimulatory molecules such as CD40, B7-1 (CD80), and B7-2 (CD86).  
Activated B cells enter one of two pathways.  They can either become short-lived plasma 
cells or they enter a follicle to establish a germinal centre.  In the germinal centre, B cells can 
evolve from the production of IgM and IgD to other isotypes such as IgG, IgA and IgE.  This 
process is called class-switching and can occur through a mechanism of gene rearrangement 
analogous to the process of TCR and B cell receptor gene segment rearrangement (Bonilla 
and Oettgen, 2010). 
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2.3.2 T cell  
 
Figure 2.4:  Expansion of antigen specific naïve TH0 cells on interaction with APC 
expressing MHC class II/peptide complexes.  Depending on the type of APC and the 
cytokine (arrows) at the site of antigen encounter, TH0 cells can move along one of several 
differentiation pathways (Bonilla and Oettgen, 2010). 
 
T cells regulate immune responses by limiting tissue damage due to autoreactive or excessive 
inflammatory immune response.  It is a major component of the adaptive immune system 
(Rabb, 2002) and can directly eliminate pathogens by killing infected target cells and can 
function as helper cells (involving direct cellular contact), signal cytokines to enhance B and 
T cell responses, as well as activate mononuclear phagocytes.  T cell antigen receptors can 
only recognize antigens when it is presented on the surface of another cell by MHC 
molecules (Nairin and Helbert, 2005).  The T cells that recognizes antigen peptides derived 
from the extracellular environment are called T helper (TH) cells (Helbert, 2006).  TH cells 
produce a range of cytokines on activation.  There are two main categories of TH cells, 
namely TH1 and TH2. Each of these cells produces a mutually exclusive panel of cytokines.  
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TH1 cells differentiate from naïve TH0 precursors under the influence of IL-12 (Figure 2.4). 
These cells produce IFN γ and IL-2.  Cytokines from TH1 cells drive cell mediated responses, 
activates mononuclear phagocytes, NK cells and cytotoxic T cells for killing intracellular 
microbes and virally infected target cells.  Much attention has been given to evaluating the 
contribution of the various T-cell subsets to immunity to intracellular parasites and bacteria. 
As previously established, CD4 lymphocytes may control the parasite/bacterial load, 
however, increasing evidence is accumulating on the role played by CD8 and T lymphocytes 
in reducing the growth of these microorganisms (Milon and Lious, 1993). 
TH2 cells produce IL-4, IL-5, IL-10 and IL-13.  Their development is initiated by IL-4 and 
the transcription factor GATA-3.  Cytokines released from TH2 enhances antibody 
production, aspects of hypersensitivity and parasite-induced immune responses 
(eosinophilopoiesis) (Bonilla and Oettgen, 2010).  
 
2.4 Immune homeostasis 
A balance in the innate and adaptive immune responses is important in maintaining optimum 
health.  Even though these two systems are important in protecting the body from invading 
pathogens, unregulated over activity can lead to pathology (Magcwebeba, 2008).  Persistent 
and dysregulated inflammation combined with an exaggerated immune response is a 
contributing factor to cystic fibrosing lung disease (Fayon, 2006).  Chronic inflammation, 
which results from innate immune signals, such as the activation of TLRs, and adaptive 
signals including TH1 cytokine release, can lead to the development of Chron’s disease 
(Arranz, et al., 2008) and is an important risk factor for the development of cancer (Kundu 
and Surh, 2008; McKay, et al., 2008).  Unregulated chronic inflammation can result in 
necrosis of surrounding tissue due to prolonged release of reactive oxygen species (ROS).  It 
is suggested that chronic immune activation plays a central role in the pathogenesis of 
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immunodeficiency, CD4+ depletion and T cell energy.  These are all characteristic of HIV-1 
infection (Leng, et al., 2002).  The expression of several pro-inflammatory cytokines governs 
the expression of COX-2 which has been implicated in inflammation, fibrogenesis and 
carcinogenesis (Baskaran, et al., 2009).  Dominant TH1 immune response suppresses humoral 
immunity increasing the susceptibility of the host to bacterial and parasitic infections.  The 
host’s susceptibility to viral infections is increased when there is a suppression of TH1 and/or 
dominating TH2 immune response.  The susceptibility of the host to extracellular infections is 
increased with the suppression of the TH2 immune response e.g. the development of 
opportunistic infections in individuals with HIV/AIDS (Magcwebeba, 2008). 
 
2.5 Concluding remarks 
Sutherlandia frutescens is an old Cape remedy used for various ailments.  According to 
tradition, the virtues of this plant extends to include cold, influenza, chicken pox, 
inflammation, arthritis, etc. (van Wyk, et al., 2009).  Some of Sutherlandia frutescens 
medicinal properties are due to its effects on the immune system.  This would include either 
the stimulation or suppression of certain immune pathways decreasing the susceptibility of 
the host to intracellular and/or extracellular pathogens.  The aim of this study is to monitor 
the effects of Sutherlandia frutescens on inflammation, cellular immunity and humoral 
immunity.  
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Chapter 3: Validation of whole blood cell assays to monitor immune function 
 
3.1 Introduction 
3.1.1 In vitro and in vivo methods 
To investigate the immune system thoroughly, both in vitro and in vivo experiments are 
necessary.  In vitro experiments play an important role in monitoring certain biomarkers of 
the immune system in the presence or absence of endotoxin. However, data collected from in 
vitro experiments may lead to incorrect beliefs regarding the effects on the immune system as 
the microenvironment of mammals cannot be mimicked.  Investigation of both innate and 
acquired immunity in human subjects is limited by ethical and moral concerns “to do no 
harm” (Sulliman and Wang, 2006).  Therefore, evaluation of the human immune system must 
be completed in vitro first to establish a base line before in vivo studies can be employed. 
Even though much can be learnt from in vitro studies, these model studies may not be able to 
achieve the precise complexity which includes mimicking the microenvironment of intact 
mammals.  After completing an in vitro experiment, it is recommended that the experiment is 
repeated in an animal model to ensure that the data gathered has in vivo relevance.  Animal 
models are useful to test various hypotheses in vivo, however, there are factors such as the 
complexity of the animal system in which the study is conducted, that need to be taken into 
account before extracting information from experimental data employing higher eukaryotes 
and applying this data to the human physiology (Sulliman and Wang, 2006).  
 
Due to this study being the first of its kind for Sutherlandia frutescens, in vitro methods were 
employed.  Running in vitro assays using whole blood cells was preferred as they mimic the 
in vivo environment more accurately than isolated monocytes with reference to the immune 
system (Pool and Bouic, 2001).     
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3.1.2 Sutherlandia frutescence and the immune system 
The ability to differentiated between self and non self to protect the host from pathogenic 
micro organisms is vital (Sulliman and Wang, 2006; Meyer, 2009).  Pathogens can replicate 
intracellularly or extracellularly.  Due to this, different aspects of the human immune system 
are evolving to protect the host against pathogenic invasion (Meyer, 2009).  The immune 
defense system of human hosts mainly includes inflammation, humoral and cellular 
immunity.  Inflammation describes the host’s immediate response to infection or damage 
(Griffin, et al., 2003; Edgar, 2006; Janeway and Travis, 1994).  Humoral immunity 
contributes to the natural resistance of the host to extracellular pathogens such as fungi, 
parasites and most bacteria (Casadevall, et al., 2002).  Cellular immunity activates 
mononuclear phagocytes, natural killer (NK) cells and cytotoxic T cells for killing 
intracellular microbes and virally infected target cells (Milon and Lious, 1993). 
 
To study the human immune response to Sutherlandia frutescence, the in vitro effects on 
human whole blood cells requires careful monitoring.  Most studies done on the immune 
response have used the in vitro whole blood culture system (Pike, 1975). 
 
Before the immune activity of Sutherlandia frutescence can be evaluated, assay systems to 
monitor cytotoxicity, inflammation, cellular immunity and humoral immunity must be 
validated.  
 
Toxicity can be measured by assessing cellular damage.  Damage to cells causes the leakage 
of lactate dehydrogenase (LDH).  The amount of LDH released from the cells into the culture 
medium indicates the toxicity of a substance.  
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Inflammation illustrates the body’s immediate response to harmful stimuli (Griffin, et al., 
2000).  The use of immune biomarkers in molecular epidemiology is rapidly expanding the 
field of research (Duramad, et al., 2007).  Biomarkers can be defined as “a characteristic that 
is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacological response to a therapeutic intervention” (O’Hara Jr., 
et al., 2006).  Biomarkers closely linked to the mechanism of a pharmaceutical action can be 
used to measure the potency of that agent.  IL-6 is a cytokine which has pro-inflammatory 
actions hence the synthesis of IL-6 by whole blood cells was used as a biomarker for 
inflammation.  Humoral immunity is responsible for the elimination of extracellular 
pathogens such as bacteria and toxic molecules which is brought about by the production of 
antibodies (Griffin, et al., 2003; Medeiros, et al., 2009).  Cytokines released from TH2 cells 
enhances the production of antibodies.  TH2 cells produce IL-4, IL-5, IL-10 and IL-13 
(Bonilla and Oettgen, 2010).  The synthesis of IL-10 by whole blood cells was used as a 
biomarker to test humoral immune activity.  Cellular immunity is responsible for the 
protection against intracellular pathogens (Griffin, et al., 2003).  The differentiation of TH1 
cells from naïve TH0 cells are influenced by various cytokines.  TH1 cells produce INFγ and 
IL-2.  These cytokines facilitate cell mediated immune responses (Milon and Lious, 1993).  
The synthesis of INFγ by whole blood cells was used as a biomarker to test cellular immune 
activity. 
 
The aim of this study was to validate the biomarker assays that will be used in the research 
project. 
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3.2 Methods 
3.2.1 Blood collection  
The blood obtained was collected by the doctor/nurse at the campus clinic.  Blood from 3 
healthy male volunteers, not on any medication was used.  Blood samples were collected by 
venipuncture directly into heparinised vacuum tubes.  The blood was stored at room 
temperature and used within 4 hours of collection.  Preparation of the whole blood cell 
cultures were done under sterile conditions in a laminar flow cabinet.  Approval for the study 
was received from the University of the Western Cape’s ethics committee and an informed 
consent was obtained from all participants. 
 
3.2.1.1 Whole blood cells stimulated with Lipopolysaccharide (LPS) 
Stimulated whole blood cultures contained 1 volume of 10 µg/ml LPS in dimethyl sulfoxide 
(DMSO), 10 volumes of blood and 89 volumes of RPMI-1640 medium.   Unstimulated 
whole blood contained 10 volumes of blood and 89 volumes of RPMI-1640 and 1 volume 
DMSO.  The (stimulated and unstimulated) blood (200µl/well) was incubated at 37 ˚C for 24 
hours.  Culture supernatants were then collected and assayed for LDH and IL-6.   
 
3.2.1.2 Whole blood cells stimulated with phytohaemagglutinin (PHA) 
Stimulated whole blood cultures contained 10 volumes of blood, 89 volumes of RPMI-1640 
medium and 1 volume of 1.6µg/ml PHA in RPMI.  The final concentration of PHA in the 
stimulated blood mixture was 1.6µg/ml.  Unstimulated whole blood contained 10 volumes of 
blood and 90 volumes of RPMI.  Stimulated and unstimulated blood (200µl/well) cultures 
were incubated for 48 hours.  Culture supernatants were then used for IL-10 and INF γ 
assays. 
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3.2.2 Cytotoxicity 
Culture supernatants were collected after the incubation with and without immune 
stimulation. LDH was measured using a Cytotoxicity Detection kit (Biovision, USA).  The 
kit includes all the components required for the assay.  Total cellular LDH were obtained by 
lysing diluted whole blood with the detergent Triton X100.  The lysed cells were used to 
determine total cellular LDH.  Cell culture supernatants and the lysed cells were assayed on a 
96 well plate (Nunc-Immuno plate, MaxiSorp).  100µl of the kit reaction mixture was added 
to the respective wells and incubated for approximately 15 minutes.  The absorbance of the 
reaction mixtures were measured at 492nm using a plate spectrophotometer at various time 
intervals.  Cytotoxicity was expressed as the amount of LDH in supernatant as % of total 
cellular LDH.  
 
3.2.3 Cytokine analysis 
Double antigen sandwich enzyme linked immune sorbent assays (DAS ELISAs) (e-
Bioscience, Germany) were used to measure cytokine release from the supernatants of the 
whole blood cells cultures. Nunc maxisorp (NuncTM, Denmark) plates were used for the 
assays.  This kit contained all the reagents, buffers and diluents needed for performing 
quantitative ELISAs.  The ELISAs were carried out according to the manufacturer’s 
instructions. In summary: 96 well plates were coated with primary antibody against the 
respective cytokine and incubated overnight at 4 ˚C.  After incubation, the plates were 
washed with sterile phosphate buffered saline containing 0.05%Tween-20.  Non-specific 
binding sites were then blocked with assay diluent for 1 hour at ambient temperature after 
which the wells received either recombinant human cytokine standards or sample.  The plate 
was sealed and incubated for 2 hours at ambient temperature on a shaker.  After incubation 
the wells were washed.  The wells then received Biotin-conjugated antibody against the 
 
 
 
 
  
 
45 
respective cytokine.  The plate was incubated for 1 hour at ambient temperature on a shaker 
followed by washing as before.  The wells then received Avidin-HRP conjugate.  The plate 
was then incubated for 30 minutes at ambient temperature on a shaker.  After the last wash, 
the bound peroxidase was monitored by addition of Tetramethylbenzidine solution (substrate 
solution) to each well, after which the plate was incubated for approximately 15 minutes.  
The reaction was stopped by adding 2M H2SO4 to each well.  The absorbance was read at 
450nm on an ELISA plate reader. Excel was used to generate a standard curve for each 
ELISA plate which was used to determine the cytokine concentrations of the culture 
supernatants. 
 
3.3 Results and discussion 
3.3.1 Cytotoxicity 
 
Figure 3.1: Standard curve for cytotoxicity.  A graphical representation of the absorbance of 
the reaction mixtures measured at 492nm at various total cell lysate concentrations after 10 
minutes of incubation. Data are presented as the mean n=2.  n is the number of replicates 
used in the experiment.  
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The total LDH from the blood cultures was considered to be 100% toxicity (after being 
released into the medium).  A standard curve was constructed from dilutions of the 100% 
toxicity sample.  There exist a good correlation between the average absorbance and the LDH 
level (R2=0.998) as reflected in Figure 3.1.  
 
3.3.2 Inflammatory activity 
 
 
 
 
 
 
 
 
Figure 3.2: Standard curve for IL-6.  The standard curve was assayed by the DAS ELISA  
according to the instructions of the manufacturer.  Data are presented as the mean n=2.  n is 
the number of replicates used in the experiment.  
 
Supernatants from LPS stimulated cultures were analyzed for inflammatory activity using IL-
6 as a biomarker.  Figure 3.2 represents the standard curve obtained using the IL-6 ELISA kit 
There exist a good correlation in the release of IL-6 (R2=0.966).  The IL-6 released at 0µg/ml 
for stimulated whole blood cell cultures was 8793.7±914.6pg/ml while the IL-6 released by 
the unstimulated blood was 116.5±31.39pg/ml.  This data shows that there is a statistically 
significant difference (P≤0.001) between the IL-6 released from the stimulated and 
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unstimulated whole blood cell cultures showing that this biomarker assay can be used to 
monitor inflammatory activity. 
 
3.3.3 Humoral immunity 
 
 
 
 
 
 
 
 
Figure 3.3: Standard curve for IL-10.  The standard curve was assayed by the DAS ELISA 
according to the instructions of the manufacturer. Data are presented as the mean n=2.  n is 
the number of replicates used in the experiment.  
 
Supernatants from PHA stimulated cultures were analyzed for humoral immune activity 
using IL-10 as a biomarker.  Figure 3.3 represents the standard curve obtained using the IL-
10 ELISA kit.  There exist a good correlation in the release of IL-10 (R2=0.997).  The IL-10 
released at 0µg/ml for stimulated whole blood cell cultures was 22.6±3.7pg/ml while the IL-
10 released by the unstimulated blood was 2.6±11.9pg/ml.  This data shows that there is a 
statistically significant difference (P=0.003) between the IL-10 released from the stimulated 
and unstimulated whole blood cell cultures showing that this biomarker assay can be used to 
monitor humoral immune activity. 
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3.3.4 Cellular immunity 
 
 
 
 
 
 
 
 
Figure 3.4: Standard curve for INF γ.  The standard curve was assayed by the DAS ELISA 
according to the instructions of the manufacturer.  Data are presented as the mean n=2.  n is 
the number of replicates used in the experiment.  
 
Supernatants from PHA stimulated cultures were analyzed for cellular immune activity using 
INF γ as a biomarker.  Figure 3.4 represents the standard curve obtained using the INF γ 
ELISA kit. There exist a good correlation in the release of INF γ (R2=0.992).  The release of 
INF γ at 0µg/ml for stimulated whole blood cell cultures was 891.1±661.0pg/ml while the 
INF γ released by unstimulated blood was 11.1±5.8pg/ml.  This data shows that there is a 
statistically significant difference (P=0.009) between the INF γ secretions of the stimulated 
and unstimulated whole blood cell cultures indicating that this biomarker assay can be used to 
monitor cellular immune activity. 
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3.4 Concluding remarks 
Increasing emphasis is being placed on biomarkers as indicators for certain inflammatory and 
auto-immune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus 
erythematosus.  Expression of cell surface markers and cytokines produced by T and B 
lymphocytes can lead to a more detailed description of disease activity in patients and serve 
as indicators of the patient’s response to treatment (O’Hara Jr., et al., 2006).  It is for this 
reason that cytokines are commonly used as diagnostic biomarker to monitor the effects of a 
pharmaceutical on immune pathways (Fiala and Veerhuis, 2010).  The in vitro cell culture 
assay is based on the fact that mitogens can stimulate whole blood cells.  Studies have shown 
that the amount of cytokines released by cultured cells is directly proportional to the 
endotoxin concentration of the culture medium (Pool, et al., 1998).  Running in vitro assays 
via whole blood cell cultures is preferred as it represents the in vivo environment more 
accurately than isolated monocytes in terms of the immune system (Pool and Bouic, 2001).     
 
The above data shows that mitogen activated whole blood cultures can be used as an effective 
method to monitor immune pathways as there is a good correlation in the release of the 
cytokines tested. 
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Chapter 4: The screening of Sutherlandia frutescens for immune modulating activity using in 
vitro whole blood culture assays 
 
3.1 Introduction 
Sutherlandia frutescens is a perennial, flowering shrub of the pea family 
(Fabaceae/Leguminosa) (Sia, 2004).  It is a commonly used, versatile medicinal herb that is 
indigenous to Africa (Fernandes, et al., 2004; Ojewole, 2008).  Widely known as cancer bush, 
Sutherlandia frutescens has been used in the traditional medical systems of different cultural 
groups in Africa such as Zulu, Xhosa, Sotho, Khoi-San and Cape Dutch. Traditionally, 
Sutherlandia frutescens has been used for a variety of illness conditions (van Wyk and 
Albrecht, 2008).   
The plant is used by many cultural groups for fever, poor appetite, indigestion, gastritis, 
oesophagitis, peptic ulcers, dysentery, cancer tonic (prevention and treatment), diabetes, cold, 
influenza, cough, asthma, chronic bronchitis, kidney and liver conditions, rheumatism, heart 
failure, urinary tract infections and stress and anxiety (van Wyk and Albrecht, 2008). 
According to Medicinal Plants of the World by van Wyk and Wink (2004), it is also used as a 
bitter tonic, an adaptogen, appetite enhancer, tuberculosis remedy, immune stimulating 
properties, treatment for wasting in cancer and AIDS patients and topically used to treat 
burns, wounds and inflammatory skin conditions. Sutherlandia frutescens has also been used 
for chronic fatigue syndrome, rheumatoid arthritis, osteoarthritis, menopausal symptoms and 
clinical depression (Mills, et al., 2005). 
The medicinal properties of Sutherlandia frutescens are linked to its constituents.  The 
constituents of Sutherlandia frutescens is divided into six groups, namely free amino acids, 
L-canavanine and GABA, pinnitol, flavonoids, triterpenoid saponins and other compounds 
(van Wyk and Albrecht, 2008; van Wyk, et al., 2009).  There are three principle constituents 
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of Sutherlandia frutescens that contributes to its efficacy.  These constituents are L-
canavanine, GABA and pinnitol (Mills, et al., 2005).   
Scientific data on the effects of Sutherlandia frutescens on the immune system has not been 
well documented (Mills, et al., 2005).  Signaling pathways within the immune system is 
initiated via cytokines.  Cytokines are proteins that functions as intracellular mediators.  They 
are produced by leukocytes and act on target tissues resulting in multiple biological actions 
(Kapsimalis, et al., 2008).  Interleukin (IL) 6 is a multi-potential cytokine.  It is known to play 
a role in inflammation through the activation of T cells and differentiation of B cells.  It is 
therefore commonly used as a biomarker for inflammation (Heyen, et al., 2000).  IL-10 and 
INFγ are biomarkers used to determine T cell activity.  IL-10 upregulates humoral immunity 
and thus defends the host against extracellular pathogens.  INFγ upregulates cell mediated 
immunity and is very important for defenses against intracellular pathogens and cancer 
(Fuchs, et al., 1988). 
In this study, the immune modulating properties of Sutherlandia frutescens are evaluated.  
 
3.2 Methods 
3.2.1 Preparation of Sutherlandia frutescens 
 A 20% (w/v) extract of Sutherlandia frutescens were prepared in 94.4% ethanol by Parceval 
(Pty) Ltd pharmaceuticals (South Africa).  The leaves of the plant were crushed (sieve size~ 
2-3 mm) after which it was mixed with 94.4% ethanol at 20g/100ml ethanol.  The mixture 
was incubated overnight then pressed to separate the leaves from the tincture.  The tincture 
was then filtered to remove excess debris and stored and -4˚C.  The samples for immune 
assays were prepared by air drying 5ml of the ethanol extract.  The dried extract was then 
reconstituted with 2ml DMSO to give a final concentration of 5g leave extract/ml DMSO.  
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3.2.2 Blood collection  
The blood obtained was collected by the doctor/nurse at the campus clinic.  Blood from 3 
healthy male volunteers, not on any medication was used.  Blood samples were collected by 
venipuncture directly into heparinised vacuum tubes.  The blood was stored at room 
temperature and used within 4 hours of collection.  Preparation of the whole blood cell 
cultures were done under sterile conditions in a laminar flow cabinet.   Approval for the study 
was received from the University of the Western Cape’s ethics committee and an informed 
consent was obtained from all participants. 
 
3.2.3 Whole blood cells stimulated with Lipopolysaccharide (LPS) 
Stimulated whole blood cultures contained 1 volume of 10 µg/ml LPS in dimethyl sulfoxide 
(DMSO), 10 volumes of blood and 89 volumes of RPMI-1640 medium.   Unstimulated 
whole blood contained 10 volumes of blood and 89 volumes of RPMI-1640 and 1 volume 
DMSO.   The (stimulated and unstimulated) blood (200µl/well) was incubated at 37 ˚C for 24 
hours. Culture supernatants were then collected and assayed for LDH and IL-6.    
 
3.2.4 Whole blood cells stimulated with phytohaemagglutinin (PHA) 
Stimulated whole blood cultures contained 10 volumes of blood, 89 volumes of RPMI-1640 
medium and 1 volume of 16µg/ml PHA in RPMI.  The final concentration of PHA in the 
stimulated blood mixture was 16µg/ml.  Unstimulated whole blood contained 10 volumes of 
blood and 90 volumes of RPMI.  Stimulated and unstimulated blood (200 µl/well) cultures 
were incubated for 48 hours.  Culture supernatants were then used for IL-10 and INF γ 
assays. 
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3.2.5 Cell culture  
Sutherlandia frutescens was diluted with DMSO.  The diluted Sutherlandia frutescens 
(2µl/well) was added to wells of a 96 well plate.  Stimulated or unstimulated whole blood 
(200µl/well) was added to wells containing Sutherlandia frutescens extract.  Control cultures 
contained 2µl DMSO instead of Sutherlandia frutescens extract.  The 96 well plate was 
sealed with Platemax cyclerseal sealing film and thereafter incubated at 37 ˚C.  Plates 
containing LPS and PHA stimulated blood were incubated for 24 and 48 hours respectively. 
Assays were done in triplicate. 
 
3.2.6 Cytotoxicity 
Culture supernatants were collected after the incubation with and without immune 
stimulation. LDH was measured using a Cytotoxicity Detection kit (Biovision, USA).  The 
kit includes all the components required for the assay.  Total cellular LDH were obtained by 
lysing diluted whole blood with the detergent Triton X100.  The lysed cells were used to 
determine total cellular LDH. Cell culture supernatants and the lysed cells were assayed on a 
96 well plate (Nunc-Immuno plate, MaxiSorp).  100µl of the kit reaction mixture was added 
to respected wells and incubated for approximately 15 minutes.  The absorbance of the 
reaction mixtures were measured at 492nm using a plate spectrophotometer at various time 
intervals.  Cytotoxicity was expressed as the amount of LDH in supernatant as % of total 
cellular LDH.  
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3.2.7 Cytokine analysis 
Double antigen sandwich enzyme linked immune sorbent assay (DAS ELISAs) (e-
Bioscience, Germany) was used to measure cytokine release from the supernatants of the 
whole blood cells cultures.  Nunc maxisorp (NuncTM, Denmark) plates were used for the 
assays.  This kit contained all the reagents, buffers and diluents needed for performing 
quantitative ELISAs.  The ELISAs were carried out according to the manufacturer’s 
instructions.  In summary: 96 well plates were coated with primary antibody against the 
respective cytokine and incubated overnight at 4 ˚C.  After incubation, the plates were 
washed with autoclaved phosphate buffered saline containing 0.05%Tween-20.  Non-specific 
binding sites were then blocked with assay diluent for 1 hour at ambient temperature after 
which the wells received either recombinant human cytokine standards or sample.  The plate 
was sealed and incubated for 2 hours at ambient temperature on a shaker.  After incubation 
the wells were washed.  The wells then received Biotin-conjugated antibody against the 
respective cytokine.  The plate was incubated for 1 hour at ambient temperature on a shaker 
followed by washing as before.  The wells then received Avidin-HRP conjugate.  The plate 
was then incubated for 30 minutes at ambient temperature on a shaker.  After the last wash, 
the bound peroxidase was monitored by addition of Tetramethylbenzidine solution (substrate 
solution) to each well, after which the plate was incubated for approximately 15 minutes.  
The reaction was stopped by adding 2M H2SO4 to each well.  The absorbance was read at 
450nm on an ELISA plate reader.  Excel was used to generate a standard curve for each 
ELISA plate which was used to determine the cytokine concentrations of the culture 
supernatants. 
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3.2.7 Statistical analysis 
Experiments were performed three times in duplicate. All data is presented as a mean ± 
standard deviation (SD).  Data was statistically analyzed via one-way ANOVA (P<0.05) and 
regression analysis.  
 
3.3 Results 
3.3.1 Cytotoxicity  
The cytotoxicity of Sutherlandia frutescence was determined by evaluating the Lactate 
dehydrogenase (LDH) activity in cell culture supernatants.  The toxicity Sutherlandia 
frutescens was tested at concentrations ranging from 0µg/ml - 5000µg/ml. Results obtained 
concludes that Sutherlandia frutescence does not cause LDH leakage at any of the 
concentration.  This indicates that Sutherlandia frutescence is not toxic to the cells at any of 
the concentrations used for this study. 
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3.3.2 The inflammatory activity of Sutherlandia frutescens 
 
 
 
 
 
 
 
 
 
Figure 4.1: The inflammatory activity of Sutherlandia frutescens.  Induction of IL-6 (pg/ml) 
of whole blood cultures in-vitro by LPS, in the presence of various concentrations of 
Sutherlandia frutescens. An asterisk (*) designates the significant difference (P<0.05) to the 
control.  Data are presented as the mean n=6.  n is the number of replicates used in the 
experiment.  All three donors were assayed simultaneously in duplicate to reduce the 
variables and to ensure accuracy. 
 
The addition of Sutherlandia frutescens to stimulated blood has no effect on the release of  
IL-6 at concentrations between 0µg/ml-500µg/ml (Figure 4.1).  However, there is a 
significant decrease (P<0.05) in the release of IL-6 at 5000µg/ml.  The addition of 
Sutherlandia frutescens at 5000µg/ml to the stimulated whole blood cell cultures resulted in a 
significant lower release of IL-6 as compared to the control (P<0.05).  The addition of 
Sutherlandia frutescens to unstimulated whole blood cell cultures had no effect on IL-6 
concentrations.  Total IL-6 produced by unstimulated cultures was <10% of the level 
produced by stimulated cultures. 
 
* 
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3.3.3 The effects of Sutherlandia frutescens on humoural immunity 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: The effects of Sutherlandia frutescens on the release of IL-10 secreted by PHA 
stimulated whole blood cells. An asterisk (*) designates the significant difference (P<0.05) to 
the control.  Data are presented as the mean n=6.  n is the number of replicates used in the 
experiment.  All three donors were assayed simultaneously in duplicate to reduce the 
variables and to ensure accuracy. 
 
The addition of Sutherlandia frutescens to stimulated blood has no effect on the release of  
IL-10 at the concentration of 50µg/ml.  However, there is a significant difference (P<0.05) in 
the release of IL-10 at 500µg/ml and 5000µg/ml as depicted in Figure 4.2.  The addition of 
Sutherlandia frutescens at concentrations of 500µg/ml and 5000µg/ml to stimulated whole 
blood cell cultures  resulted in a significantly lower release of IL-10 compared to that of the 
control (P<0.05).  The addition of Sutherlandia frutescens to unstimulated blood had no 
effect on IL-10 concentrations.  Total IL-10 produced by unstimulated cultures were <10% of 
the level produced by stimulated cultures. 
 
* 
* 
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3.3.4 The effects of Sutherlandia frutescens on cellular immunity 
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Figure 4.3:  The effects of Sutherlandia frutescens on the release of INF γ secreted by PHA 
stimulated whole blood cells of three donors.  Data are presented as the mean n=2.  n is the 
number of replicates used in the experiment.  All three donors were assayed simultaneously 
in duplicate to reduce the variables and to ensure accuracy. 
 
It was observed (Figure 4.3) that there is a wide variation in the release of INF γ at the 
various concentrations of Sutherlandia frutescens between the 3 donors tested.  In donor 1, 
the addition of Sutherlandia frutescens at concentrations 500µg/ml and 5000µg/ml 
suppressed the release of INF γ.  In donor 2, the release of INF γ was increased at 
concentrations 500µg/ml and 5000µg/ml and in donor 3 there was no effect on the release of 
INF γ.  
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Due to the different responses by the above donors, whole blood cells from an additional 3 
donors were collected and assayed.  Smaller increments of Sutherlandia frutescens 
concentrations were used to assess the release of INF γ more accurately.  The results obtained 
were as follows: 
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Figure 4.4:  The effects of Sutherlandia frutescens on the release of INF γ secreted by PHA 
stimulated whole blood cells of three donors.  Data are presented as the mean n=3.  n is the 
number of replicates used in the experiment.  
 
These assays tested the release of INF γ at concentrations ranging from 0µg/ml – 5000µg/ml 
in increments of 3, i.e. 3 fold dilution.  The assays were conducted in triplicate for accuracy 
and consistency.  The data above (figure 4.4) depicts an average of INF γ released as a 
percentage of the control.  It was observed that there is a wide variation in the release of INF 
γ at the various concentrations of Sutherlandia frutescens between the above 3 donors tested 
(Figure 4.4).  Data collected for donor 4 shows a slight suppression in the release of INF γ. 
Donor 5 showed a marked increase in the release of INF γ at all the concentrations of 
Sutherlandia frutescens tested.  In donor 6 there was neither an increase nor decrease in the 
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release of INFγ. Despite the larger donor sampling pool, the wide variation in the release of 
INF γ at all the concentrations tested was again noted indicating donor specific variations to 
Sutherlandia frutescens.  
 
3.4 Discussion 
The immune system’s main function is to protect the host from infection.  Sometimes the 
immune response to pathogens such as measles or small pox may be so powerful that the 
initial infection provides a life long protection.  Sometimes the immune response is so weak 
that infection usually results in long term infectious disease or the individual becomes a 
“healthy carrier” of the antigen (Sun, 2008). 
The aim of this study was to evaluate the effects of Sutherlandia frutescens on the immune 
pathways as this herb is used by many cultural groups for a wide range of illness conditions 
(table 1).  It is used in conditions which require either the suppression or stimulation of 
certain immune pathways.  Sutherlandia frutescens was screened for toxicity at various 
concentrations.  Results showed that Sutherlandia frutescens was non toxic at all the 
concentrations tested.  
Various concentrations of Sutherlandia frutescens extract were screened for its effects on 
inflammation and T cell activity by using in vitro human whole blood cultures.   
Inflammation is an intricate biological response of the host’s immune system to harmful 
stimuli (Medeiros, et al., 2009).  IL-6 is a pleiotropic cytokine which has a pro-inflammatory 
action (Ahmed and Ivashkiv, 2000).  IL-6 was used as a biomarker to determine the effect of 
Sutherlandia frutescens extract on inflammation.  
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Whole blood cell cultures were stimulated with the extract as explained in the methods 
section.  Exposure to a pharmaceutical may initiate either an elevation or suppression in the 
levels of IL-6 released.  
The supernatant of the stimulated and unstimulated whole blood cell cultures incubated with 
Sutherlandia frutescens were screened using the whole blood cells from 3 healthy male 
donors simultaneously and duplicated for consistency.  
 Sutherlandia frutescens at high concentrations inhibits IL-6 indicating that the extract has 
anti inflammatory properties.  The anti inflammatory properties of Sutherlandia frutescens 
validate its uses as an anti-inflammatory agent.  It is reported to have a possible application in 
the treatment of septic shock and chronic inflammation.  The anti inflammatory properties 
have been linked to flavonoids sutherlandin A-D, L-canavanine and pinitol (Anfossi, et al., 
1999; Ojewole, 2004; Avula, et al., 2010).  Flavonoids are known for its anti inflammatory 
effect (Evans, 2002).  L-canavanine prevents the arginine derived synthesis of nitric oxide 
(NO).  L-canavanine is an arginine antagonist that selectively inhibits NO synthase causing 
vasoconstriction hence contributes to Sutherlandia frutescens anti-inflammatory action 
(Anfossi, et al., 1999; Abramson, 2005).  Pinnitol decreases the production of pro-
inflammatory cytokines (Ojewole, 2004).  The proven anti inflammatory action of 
Sutherlandia frutescens validates its anecdotal use in the treatment of oesophagitis, gastritis, 
dysentery, inflammatory skin conditions, rheumatoid arthritis, osteoarthritis, asthma, 
bronchitis and cystitis (Albrecht, 2008; Gericke, et al., 2001; van Wyk and Albrecht 2008; 
van Wyk and Wink 2004).   Sutherlandia frutescens can also be used in the management of 
cardiovascular diseases as enhanced inflammation is involved in the development and 
progression of atherosclerosis (Gokkusu, et al., 2010). 
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The cytokines IL-10 and INFγ were used as biomarkers to determine the effect of 
Sutherlandia frutescens on T cell activity.  IL-10 directs the differentiation of TH2 cells which 
are responsible for strong antibody production, eosinophil activation, and inhibition of several 
macrophage functions.  It thus provides phagocyte-independent protective responses.  INFγ 
coordinates a diverse array of cellular programs including the differentiation of T cells (T0) 
into TH1 cells.  TH1 cells mainly develop during infections caused by intracellular bacteria and 
may trigger phagocyte-mediated host defense (Romagnani, 1999).  
Whole blood cell cultures were stimulated with PHA and incubated with Sutherlandia 
frutescens as explained in the methods section.  The results obtained indicate that 
Sutherlandia frutescens hinders the differentiation of TH2 cells at higher concentrations, 
hence suppresses the phagocyte independent host response.  Sutherlandia frutescens is 
commonly used in the management of asthma.  Asthma can be defined as the increased 
irritability of the bronchial tree resulting in narrowing of the airways (Underwood, 2004). 
Asthma is a common clinical manifestation of an allergy.  An immunological pathway driven 
by TH2 cells such as the production of eosinophils aids this immune response (Arshad, 2005). 
Eosinophils are non-dividing immune cells that originate in the bone marrow (DiScipio and 
Schraufstatter, 2007).  It functions as effector cells in the pathogenesis of allergic 
inflammatory reactions such as bronchial asthma (Chihara, et al., 1999).  The data collected 
validates the anecdotal use of Sutherlandia frutescens in the management of asthma as the 
suppression of TH2 differentiation at high concentrations results in a decrease in eosinophil 
activation.  Even though the results obtained validate the use of Sutherlandia frutescens in the 
management of asthma, it would not be effective in eliminating extra-cellular bacteria such as 
Salmonella enterica and Listeria moncytogenes which are food borne pathogens with clinical 
features including gastroenteritis and septicemia (Fablet, et al., 2006; Braun and Cossart, 
2000).  
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The data collected shows a good correlation between the effects of Sutherlandia frutescens 
on the release of IL-6 and IL-10 at the higher concentrations tested.  It can be noted that 
Sutherlandia frutescens down regulates the release of both cytokines, however, IL-10 is 
suppressed at ≥500µl/ml whereas the suppressing effect of Sutherlandia frutescens on the 
release of IL-6 takes place at ≥5000µl/ml.  This indicates that the TH2 suppression by 
Sutherlandia frutescens takes place at lower concentrations than the anti inflammatory effect. 
 
Sutherlandia frutescens is commonly used to treat many viral infections such as chickenpox, 
influenza and gonorrhea.  The anti-viral properties have been linked to L-canavanine and is 
effective in the management of influenza and retroviruses including HIV (Mills, et al., 2005).  
INFγ coordinates the differentiation of TH0 cells into TH1 cells.  TH1 cells drives the cell 
mediated immune response which is mainly involved with infections caused by intra-cellular 
bacteria and cancer (Romagnani, 1999; Milon and Lious, 1993). 
The effects of Sutherlandia frutescens on the release of INFγ are depicted above in Figures 
4.3 and 4.4 respectively. It is noted that the results obtained from the donors varied 
considerably.  In some donors the release of INFγ was less than that of the control.  In some 
donors the release of INFγ was markedly higher than that of the control and in other donors, 
there were neither an increase nor decrease in the release of INFγ.  This shows that 
Sutherlandia frutescens, at the concentrations tested, has individual specific effects on the 
differentiation of T cells (T0) into TH1 cells.  
The results obtained for INFγ can serve to motivate that science cannot always conclusively 
validate the exact mechanism of allelopathy hence the evolution of technology is an ongoing 
process. 
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3.5 Concluding remarks 
The current study indicates the suppression of the inflammatory and phagocyte independent 
host’s response at high concentrations of Sutherlandia frutescens with no effect on the release 
of IL-6 and IL-10 at the lower concentrations. Sutherlandia frutescens was found to be donor 
specific for INFγ as it acted in both inhibitory and stimulatory manners on the phagocyte-
mediated host response.  This is illustrated with the up and down regulation of INFγ released 
in the stimulated whole blood cells of the 6 donors tested.  A possible reason for the lack of 
scientific data available regarding Sutherlandia frutescens and the immune system as 
mentioned by Mills, et al. (2005) may be linked to variation in data regarding the release of 
INFγ as this is a cytokine involved in cellular immunity.  Cellular immunity is responsible for 
activating mononuclear phagocytes, NK cells and cytotoxic T cells for killing intra-cellular 
pathogens and cancer (Milon and Lious, 1993).  The results indicate that Sutherlandia 
frutescens may in fact upregulate the TH1 process in some donors and this will help these 
donors fight intra-cellular pathogens and cancer. However, Sutherlandia frutescens is contra-
indicated in the treatment of intra-cellular pathogens and cancer where INFγ is down 
regulated.  Further investigation of the effects of Sutherlandia frutescens on cellular 
immunity on a larger sample pool is therefore recommended. 
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Chapter 5: Summary, Concluding remarks and Recommendations 
 
4.1 Summary 
Human beings live in an environment surrounded by microorganisms – viruses, bacteria, 
fungi and parasites, many of which can be pathogenic if the host’s body is not physiologically 
prepared to initiate and drive responses against these pathogens.  An efficient immune system 
is vital in preventing systemic infections which can be fatal.  Cytokines are low-molecular 
weight proteins that are essential in driving immune responses.  They act through binding to 
specific cell-surface receptors initiating specific cellular functions or suppressing certain 
cellular activities.  Interleukin (IL)-6 is linked to the innate immunity and is responsible for 
inducing the initial acute inflammatory response brought about by a breach in the first line of 
immune defenses.  Antigens are passed on to the adaptive immunity by antigen presenting 
cells (APC).  Interferon gamma (INFγ) is the cytokine that initiates the differentiation of 
naïve TH0 cells to TH1.  This drives the cell mediated immunity which activates mononuclear 
phagocytes, NK cells and cytotoxic T cells for killing intracellular microbes such as virally 
infected target cells and cancers.  On the other hand, the development of TH2 cells produces 
IL-4, IL-5, IL-10 and IL-13.  These cytokines increase antibody production, aspects of 
hypersensitivity, parasite induced immune responses and humoral immunity.  
Pharmaceuticals can play an active role in modulating immune responses.  It can up regulate, 
down regulate, inhibit or have no effect on certain pathways.  Limited literature on the 
biological activities of herbs exists with even less literature on indigenous South African 
herbs. Past studies on indigenous South African herbs focused mainly on the 
pharmacokinetics of the herb’s secondary metabolites using HPLC and GC-MS.  No previous 
studies examining the immunological effects of Sutherlandia frutescens has been done 
despite its wide range of anecdotal uses.  The aim of this study was to evaluate the immune 
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modulating activity of Sutherlandia frutescens using in vitro methods.  The study focused on 
monitoring the release of the main cytokines involved in inflammation and T cell 
differentiation.  
Results were consistent with some of Sutherlandia frutescens anecdotal uses such as 
bronchial asthma, bronchitis, oesophagitis, gastritis, dysentery, inflammatory skin conditions, 
rheumatoid arthritis, osteoarthritis and cystitis.  These conditions require a decrease in the 
release of IL-6 and/or IL-10 which are the cytokines involved in inflammation and humoral 
immunity respectively. 
The effects of Sutherlandia frutescens on cellular immunity has proven to be donor specific 
as the herb acted in both stimulatory and inhibitory manners on the phagocyte mediated host 
response.  The lack of scientific data on the biological effects of Sutherlandia frutescens on 
the immune system may be linked to its donor specific effects on cellular immunity. 
.  
4.2 Concluding remarks 
The effect of herbal medicine on the immune system can be screened effectively using in 
vitro whole blood cell cultures.  Sutherlandia frutescens was not toxic at any of the 
concentrations used in this study.  In vitro data generated by this study support Sutherlandia 
frutescens use in the treatment of inflammatory conditions and allergies such as bronchial 
asthma.  In terms of cellular immunity, Sutherlandia frutescens was found to be donor 
specific.  This study provides scientific evidence validating some of the anecdotal uses of 
Sutherlandia frutescens requiring the suppression of certain immune pathways.  
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4.3 Recommendations 
This study is the first of its kind monitoring the activity of Sutherlandia frutescens on 
inflammation and T cell differentiation.  Methods to improve this work may include isolating 
specific compounds in Sutherlandia frutescens such as L-canavanine, to clarify its effect on 
cellular immunity.  This compound is said to be responsible for Sutherlandia frutescens 
antiviral activities against retroviruses including HIV.  As the management of HIV is a major 
concern for the health sector of South Africa, validating the use of Sutherlandia frutescens 
against retroviruses would be beneficial.  Further investigations exploring the effects of 
Sutherlandia frutescens on immune pathways in an in vivo system may be required to 
validate the results obtained in this in vitro study.  Water or low-medium alcoholic 
extractions of Sutherlandia frutescens is more commonly used anecdotally.  Therefore, when 
preparing the herb sample, a dosage form closer to what is commonly used by the general 
public represents the ideal. 
 
 
 
 
 
